Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
8.92
-0.07 (-0.78%)
Mar 3, 2026, 4:00 PM EST - Market closed

Emergent BioSolutions Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
205.499.5111.7642.6576.1
Cash & Short-Term Investments
205.499.5111.7642.6576.1
Cash Growth
106.43%-10.92%-82.62%11.54%-7.27%
Accounts Receivable
84.2154.5191159.2278.9
Inventory
343.4311.7328.9350.7344.5
Other Current Assets
29.53347.957.970.4
Total Current Assets
662.5598.7679.51,2101,270
Net Property, Plant & Equipment
205.4270.6382.8817.6800.1
Other Intangible Assets
436.5501.5566.6728.8604.6
Goodwill
---218.2224.9
Other Long-Term Assets
14.218.9194.3191.358.2
Total Assets
1,3191,3901,8233,1662,958
Accounts Payable
55.660.9112.2103.5128.9
Accrued Expenses
60.873.892.7122.2140.4
Short-Term Debt
--413.7957.331.6
Current Portion of Long-Term Debt
--413.7957.331.6
Other Current Liabilities
15.827.732.745.973.1
Total Current Liabilities
132.2162.4651.31,229374
Long-Term Debt
572.1663.7446.5448.5809.4
Other Long-Term Liabilities
91.780.876.1101.2162.8
Total Long-Term Liabilities
663.8744.5522.6549.7972.2
Total Liabilities
796906.91,1741,7791,346
Common Stock
0.10.10.10.10.1
Treasury Stock
-252.6-227.7-227.7-227.7-152.2
Additional Paid-in Capital
942.4928904.4873.5829.4
Accumulated Other Comprehensive Income
-7.5-5.2-5.73.1-16.1
Retained Earnings
-159.8-212.4-21.8738.7950.3
Shareholders' Equity
522.6482.8649.31,3881,612
Total Liabilities & Equity
1,3191,3901,8233,1662,958
Total Debt
572.1663.71,2742,363872.6
Net Cash (Debt)
-366.7-564.2-1,162-1,721-296.5
Net Cash Per Share
-6.47-10.64-22.70-34.34-5.48
Book Value
522.6482.8649.31,3881,612
Book Value Per Share
9.229.1112.6827.7029.79
Tangible Book Value
86.1-18.782.7440.7782
Tangible Book Value Per Share
1.52-0.351.628.8014.45
Updated Feb 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q